STAT

States, eager to lower drug prices, regroup after courts strike down Maryland ‘price-gouging’ law

“We’ll have to find other approaches to this problem,” one state lawmaker said about his drug pricing bill, after the Supreme Court voided a similar Maryland "price gouging" law.
Illinois Rep. Will Guzzardi, a Democrat from Chicago.

WASHINGTON — A legal setback in Maryland has state legislatures across the country re-examining their efforts to lower drug prices, with lawyers from Nevada to Illinois combing through bills to ensure they can withstand future challenges from pharmaceutical industry groups.

State lawmakers’ interest has centered on a recently voided Maryland law that would have banned generic drug companies from hiking prices to a degree the state deems “unconscionable.” An appeals court ruled the law unconstitutional last year, and though Maryland’s Democratic attorney general had aggressively contested the decision, the Supreme Court announced on Feb. 19 that it would not hear an appeal.

It is a legal reality that has already

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks